BiotechTube
Polares Medical

Polares Medical

Zug, Switzerland· Est.
polaresmedical.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $25.2M

Overview

Polares Medical is a private, clinical-stage medical device innovator targeting the large and growing market for mitral valve repair. The company is advancing a proprietary transcatheter device designed to offer a less invasive alternative to open-heart surgery for patients with mitral regurgitation. With a dual operational presence in Switzerland and the United States, Polares is positioned to navigate both European and U.S. regulatory pathways. The company is currently in the development and clinical validation phase, positioning itself in the competitive but high-reward structural heart space.

Cardiovascular

Technology Platform

Proprietary transcatheter device for minimally invasive repair of the mitral valve to treat regurgitation.

Funding History

2
Total raised:$25.2M
Series A$22M
Seed$3.2M

Opportunities

The large and growing unmet need in mitral regurgitation, especially among patients unsuitable for surgery, presents a significant addressable market.
The success of first-generation devices has paved the way for adoption of next-generation technologies that offer improvements in efficacy, ease of use, and patient applicability.
The company's novel approach could position it as an attractive acquisition target for larger medtech firms looking to strengthen their structural heart portfolios.

Risk Factors

The company faces intense competition from well-established players with significant resources and commercial infrastructure.
High technical and regulatory risks are inherent in developing a novel Class III implant, where failure in clinical trials or delays in approval could be catastrophic.
As a pre-revenue private company, it is dependent on external financing, and a downturn in the investment climate could threaten its runway.

Competitive Landscape

The transcatheter mitral valve repair market is dominated by Abbott's MitraClip, with Edwards Lifesciences (PASCAL), Medtronic, and numerous private companies developing competing technologies. Competition is based on device design, clinical evidence, physician training, and commercial reach. Polares must demonstrate clear clinical superiority or a unique mechanistic advantage to gain traction against these entrenched and well-funded competitors.

More companies in Drug Delivery & Formulation →More companies in Switzerland →